참고문헌 (174)

1. Mozaffarian, Dariush, Benjamin, Emelia J., Go, Alan S., Arnett, Donna K., Blaha, Michael J., Cushman, Mary, de Ferranti, Sarah, Després, Jean-Pierre, Fullerton, Heather J., Howard, Virginia J., Huffman, Mark D., Judd, Suzanne E., Kissela, Brett M., Lackland, Daniel T., Lichtman, Judith H., Lisabeth, Lynda D., Liu, Simin, Mackey, Rachel H., Matchar, David B., McGuire, Darren K., Mohler III, Emile R., Moy, Claudia S., Muntner, Paul, Mussolino, Michael E., Nasir, Khurram, Neumar, Robert W., Nichol, Graham, Palaniappan, Latha, Pandey, Dilip K., Reeves, Mathew J., Rodriguez, Carlos J., Sorlie, Paul D., Stein, Joel, Towfighi, Amytis, Turan, Tanya N., Virani, Salim S., Willey, Joshua Z., Woo, Daniel, Yeh, Robert W., Turner, Melanie B.. Heart Disease and Stroke Statistics—2015 Update : A Report From the American Heart Association. Circulation, vol.131, no.4, e29-e322.

   상세보기

2. Tabas, Ira, Williams, Kevin Jon, Borén, Jan. Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update and Therapeutic Implications. Circulation, vol.116, no.16, 1832-1844.

   상세보기

3. Borén, J, Olin, K, Lee, I, Chait, A, Wight, T N, Innerarity, T L. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.. The Journal of clinical investigation, vol.101, no.12, 2658-2664.

   상세보기

4. Atherosclerosis Srinivasan SR 201 62 1986 10.1016/0021-9150(86)90094-8 Low density lipoprotein retention by aortic tissue. Contribution of extracellular matrix. Srinivasan SR, Vijayagopal P, Dalferes ER, Abbate B, Radhakrishnamurthy B, Berenson GS. Low density lipoprotein retention by aortic tissue. Contribution of extracellular matrix. Atherosclerosis. 1986;62:201-208. 

   상세보기

5. de Winther, Menno P. J., van Dijk, Ko Willems, Havekes, Louis M., Hofker, Marten H.. Macrophage Scavenger Receptor Class A : A Multifunctional Receptor in Atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology, vol.20, no.2, 290-297.

   상세보기

6. Gough, Peter J., Gordon, Siamon. The role of scavenger receptors in the innate immune system. Microbes and infection, vol.2, no.3, 305-311.

   상세보기

7. 10.1097/01.mol.0000092631.86399.49 

   

8. Hansson, G철ran K, Hermansson, Andreas. The immune system in atherosclerosis. Nature immunology, vol.12, no.3, 204-212.

   상세보기

9. Businaro, Rita, Tagliani, Angela, Buttari, Brigitta, Profumo, Elisabetta, Ippoliti, Flora, Di Cristofano, Claudio, Capoano, Raffaele, Salvati, Bruno, Riganò, Rachele. Cellular and molecular players in the atherosclerotic plaque progression. Annals of the New York Academy of Sciences, vol.1262, no.1, 134-141.

   상세보기

10. Anzinger, Joshua J., Chang, Janet, Xu, Qing, Buono, Chiara, Li, Yifu, Leyva, Francisco J., Park, Bum-Chan, Greene, Lois E., Kruth, Howard S.. Native Low-Density Lipoprotein Uptake by Macrophage Colony-Stimulating Factor-Differentiated Human Macrophages Is Mediated by Macropinocytosis and Micropinocytosis. Arteriosclerosis, thrombosis, and vascular biology, vol.30, no.10, 2022-2031.

    상세보기

11. Wen, Yichuan, Leake, David S.. Low Density Lipoprotein Undergoes Oxidation Within Lysosomes in Cells. Circulation research : a journal of the American Heart Association, vol.100, no.9, 1337-1343.

    상세보기

12. Tabas, Ira. Macrophage death and defective inflammation resolution in atherosclerosis. Nature reviews. Immunology, vol.10, no.1, 36-46.

    상세보기

13. Lancet Scandinavian Simvastatin Survival Study Group 1383 344 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1383-1389. 

14. Downs, J R, Clearfield, M, Weis, S, Whitney, E, Shapiro, D R, Beere, P A, Langendorfer, A, Stein, E A, Kruyer, W, Gotto, A M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.. JAMA : the journal of the American Medical Association, vol.279, no.20, 1615-1622.

    상세보기

15. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. The New England journal of medicine, vol.339, no.19, 1349-1357.

    상세보기

16. Sacks, Frank M., Pfeffer, Marc A., Moye, Lemuel A., Rouleau, Jean L., Rutherford, John D., Cole, Thomas G., Brown, Lisa, Warnica, J. Wayne, Arnold, J. Malcolm O., Wun, Chuan-Chuan, Davis, Barry R., Braunwald, Eugene. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. The New England journal of medicine, vol.335, no.14, 1001-1009.

    상세보기

17. Mahlberg, F.H., Glick, J.M., Lund-Katz, S., Rothblat, G.H.. Influence of apolipoproteins AI, AII, and Cs on the metabolism of membrane and lysosomal cholesterol in macrophages.. The Journal of biological chemistry, vol.266, no.30, 19930-19937.

    상세보기

18. Libby, P.. The Forgotten Majority. Journal of the American College of Cardiology, vol.46, no.7, 1225-1228.

    상세보기

19. Cannon, Christopher P., Braunwald, Eugene, McCabe, Carolyn H., Rader, Daniel J., Rouleau, Jean L., Belder, Rene, Joyal, Steven V., Hill, Karen A., Pfeffer, Marc A., Skene, Allan M.. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. The New England journal of medicine, vol.350, no.15, 1495-1504.

    상세보기

20. Mills, Edward J., O'Regan, Christopher, Eyawo, Oghenowede, Wu, Ping, Mills, Fergal, Berwanger, Otavio, Briel, Matthias. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. European heart journal, vol.32, no.11, 1409-1415.

    상세보기

21. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet, vol.376, no.9753, 1670-1681.

    상세보기

22. Hegele, Robert A., Gidding, Samuel S., Ginsberg, Henry N., McPherson, Ruth, Raal, Frederick J., Rader, Daniel J., Robinson, Jennifer G., Welty, Francine K.. Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council. Arteriosclerosis, thrombosis, and vascular biology, vol.35, no.11, 2269-2280.

    상세보기

23. Cannon, Christopher P., Blazing, Michael A., Giugliano, Robert P., McCagg, Amy, White, Jennifer A., Theroux, Pierre, Darius, Harald, Lewis, Basil S., Ophuis, Ton Oude, Jukema, J. Wouter, De Ferrari, Gaetano M., Ruzyllo, Witold, De Lucca, Paul, Im, KyungAh, Bohula, Erin A., Reist, Craig, Wiviott, Stephen D., Tershakovec, Andrew M., Musliner, Thomas A., Braunwald, Eugene, Califf, Robert M.. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England journal of medicine, vol.372, no.25, 2387-2397.

    상세보기

24. Kastelein, John J.P., Sager, Philip T., de Groot, Eric, Veltri, Enrico. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia : Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. The American heart journal, vol.149, no.2, 234-239.

    상세보기

25. Villines, T.C., Stanek, E.J., Devine, P.J., Turco, M., Miller, M., Weissman, N.J., Griffen, L., Taylor, A.J.. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis). Journal of the American College of Cardiology, vol.55, no.24, 2721-2726.

    상세보기

26. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. The New England journal of medicine, vol.365, no.24, 2255-2267.

    상세보기

27. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. The New England journal of medicine, vol.371, no.3, 203-212.

    상세보기

28. Rossebø, Anne B., Pedersen, Terje R., Boman, Kurt, Brudi, Philippe, Chambers, John B., Egstrup, Kenneth, Gerdts, Eva, Gohlke-Bärwolf, Christa, Holme, Ingar, Kesäniemi, Y. Antero, Malbecq, William, Nienaber, Christoph A., Ray, Simon, Skjærpe, Terje, Wachtell, Kristian, Willenheimer, Ronnie. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. The New England journal of medicine, vol.359, no.13, 1343-1356.

    상세보기

29. Baigent, Colin, Landray, Martin J, Reith, Christina, Emberson, Jonathan, Wheeler, David C, Tomson, Charles, Wanner, Christoph, Krane, Vera, Cass, Alan, Craig, Jonathan, Neal, Bruce, Jiang, Lixin, Hooi, Lai Seong, Levin, Adeera, Agodoa, Lawrence, Gaziano, Mike, Kasiske, Bertram, Walker, Robert, Massy, Ziad A, Feldt-Rasmussen, Bo, Krairittichai, Udom, Ophascharoensuk, Vuddidhej, Fellström, Bengt, Holdaas, Hallvard, Tesar, Vladimir, Wiecek, Andrzej, Grobbee, Diederick, de Zeeuw, Dick, Grönhagen-Riska, Carola, Dasgupta, Tanaji, Lewis, David, Herrington, William, Mafham, Marion, Majoni, William, Wallendszus, Karl, Grimm, Richard, Pedersen, Terje, Tobert, Jonathan, Armitage, Jane, Baxter, Alex, Bray, Christopher, Chen, Yiping, Chen, Zhengming, Hill, Michael, Knott, Carol, Parish, Sarah, Simpson, David, Sleight, Peter, Young, Alan, Collins, Rory. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet, vol.377, no.9784, 2181-2192.

    상세보기

30. Wilson, P W, Abbott, R D, Castelli, W P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study.. Arteriosclerosis : an official journal of the American Heart Association, Inc, vol.8, no.6, 737-741.

    상세보기

31. Rubin, Edward M., Krauss, Ronald M., Spangler, Elizabeth A., Verstuyft, Judy G., Clift, Shirley M.. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature, vol.353, no.6341, 265-267.

    상세보기

32. Plump, A S, Scott, C J, Breslow, J L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.. Proceedings of the National Academy of Sciences of the United States of America, vol.91, no.20, 9607-9611.

    상세보기

33. Liu, A C, Lawn, R M, Verstuyft, J G, Rubin, E M. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice.. Journal of lipid research, vol.35, no.12, 2263-2267.

    상세보기

34. Tangirala, Rajendra K., Tsukamoto, Kazuhisa, Chun, Sam H., Usher, David, Puré, Ellen, Rader, Daniel J.. Regression of Atherosclerosis Induced by Liver-Directed Gene Transfer of Apolipoprotein A-I in Mice. Circulation, vol.100, no.17, 1816-1822.

    상세보기

35. Elam, M B, Hunninghake, D B, Davis, K B, Garg, R, Johnson, C, Egan, D, Kostis, J B, Sheps, D S, Brinton, E A. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.. JAMA : the journal of the American Medical Association, vol.284, no.10, 1263-1270.

    상세보기

36. Brown, B. Greg, Zhao, Xue-Qiao, Chait, Alan, Fisher, Lloyd D., Cheung, Marian C., Morse, Josh S., Dowdy, Alice A., Marino, Emily K., Bolson, Edward L., Alaupovic, Petar, Frohlich, Jiri, Serafini, Leny, Huss-Frechette, Ellen, Wang, Shari, DeAngelis, Debbie, Dodek, Arthur, Albers, John J.. Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease. The New England journal of medicine, vol.345, no.22, 1583-1592.

    상세보기

37. Clofibrate and niacin in coronary heart disease.. JAMA : the journal of the American Medical Association, vol.231, no.4, 360-381.

    상세보기

38. Barter, Philip J., Caulfield, Mark, Eriksson, Mats, Grundy, Scott M., Kastelein, John J.P., Komajda, Michel, Lopez-Sendon, Jose, Mosca, Lori, Tardif, Jean-Claude, Waters, David D., Shear, Charles L., Revkin, James H., Buhr, Kevin A., Fisher, Marian R., Tall, Alan R., Brewer, Bryan. Effects of Torcetrapib in Patients at High Risk for Coronary Events. The New England journal of medicine, vol.357, no.21, 2109-2122.

    상세보기

39. Schwartz, Gregory G., Olsson, Anders G., Abt, Markus, Ballantyne, Christie M., Barter, Philip J., Brumm, Jochen, Chaitman, Bernard R., Holme, Ingar M., Kallend, David, Leiter, Lawrence A., Leitersdorf, Eran, McMurray, John J.V., Mundl, Hardi, Nicholls, Stephen J., Shah, Prediman K., Tardif, Jean-Claude, Wright, R. Scott. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. The New England journal of medicine, vol.367, no.22, 2089-2099.

    상세보기

40. Curr Opin Investig Drugs McNeill E. 357 11 2010 RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases. McNeill E. RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases. Curr Opin Investig Drugs. 2010;11:357-364. 

    상세보기

41. Bailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G.S., Hansen, H.C., Chiacchia, F.S., Johansson, J., Krimbou, L., Wong, N.C.W., Genest, J.. RVX-208. Journal of the American College of Cardiology, vol.55, no.23, 2580-2589.

    상세보기

42. Nicholls, Stephen J., Gordon, Allan, Johannson, Jan, Ballantyne, Christie M., Barter, Philip J., Brewer, H. Bryan, Kastelein, John J. P., Wong, Norman C., Borgman, Marilyn R. N., Nissen, Steven E.. ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies. Cardiovascular drugs and therapy, vol.26, no.2, 181-187.

    상세보기

43. Voight, Benjamin F, Peloso, Gina M, Orho-Melander, Marju, Frikke-Schmidt, Ruth, Barbalic, Maja, Jensen, Majken K, Hindy, George, Hólm, Hilma, Ding, Eric L, Johnson, Toby, Schunkert, Heribert, Samani, Nilesh J, Clarke, Robert, Hopewell, Jemma C, Thompson, John F, Li, Mingyao, Thorleifsson, Gudmar, Newton-Cheh, Christopher, Musunuru, Kiran, Pirruccello, James P, Saleheen, Danish, Chen, Li, Stewart, Alexandre FR, Schillert, Arne, Thorsteinsdottir, Unnur, Thorgeirsson, Gudmundur, Anand, Sonia, Engert, James C, Morgan, Thomas, Spertus, John, Stoll, Monika, Berger, Klaus, Martinelli, Nicola, Girelli, Domenico, McKeown, Pascal P, Patterson, Christopher C, Epstein, Stephen E, Devaney, Joseph, Burnett, Mary-Susan, Mooser, Vincent, Ripatti, Samuli, Surakka, Ida, Nieminen, Markku S, Sinisalo, Juha, Lokki, Marja-Liisa, Perola, Markus, Havulinna, Aki, de Faire, Ulf, Gigante, Bruna, Ingelsson, Erik, Zeller, Tanja, Wild, Philipp, de Bakker, P. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet, vol.380, no.9841, 572-580.

    상세보기

44. Mackey, R.H., Greenland, P., Goff, D.C., Lloyd-Jones, D., Sibley, C.T., Mora, S.. High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events. Journal of the American College of Cardiology, vol.60, no.6, 508-516.

    상세보기

45. Khera, Amit V., Cuchel, Marina, de la Llera-Moya, Margarita, Rodrigues, Amrith, Burke, Megan F., Jafri, Kashif, French, Benjamin C., Phillips, Julie A., Mucksavage, Megan L., Wilensky, Robert L., Mohler, Emile R., Rothblat, George H., Rader, Daniel J.. Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis. The New England journal of medicine, vol.364, no.2, 127-135.

    상세보기

46. Rohatgi, Anand, Khera, Amit, Berry, Jarett D., Givens, Edward G., Ayers, Colby R., Wedin, Kyle E., Neeland, Ian J., Yuhanna, Ivan S., Rader, Daniel R., de Lemos, James A., Shaul, Philip W.. HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events. The New England journal of medicine, vol.371, no.25, 2383-2393.

    상세보기

47. Li, Xin-Min, Tang, Wai Hong Wilson, Mosior, Marian K., Huang, Ying, Wu, Yuping, Matter, William, Gao, Vivian, Schmitt, David, DiDonato, Joseph A., Fisher, Edward A., Smith, Jonathan D., Hazen, Stanley L.. Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks. Arteriosclerosis, thrombosis, and vascular biology, vol.33, no.7, 1696-1705.

    상세보기

48. Saleheen, Danish, Scott, Robert, Javad, Sundas, Zhao, Wei, Rodrigues, Amrith, Picataggi, Antonino, Lukmanova, Daniya, Mucksavage, Megan L, Luben, Robert, Billheimer, Jeffery, Kastelein, John J P, Boekholdt, S Matthijs, Khaw, Kay-Tee, Wareham, Nick, Rader, Daniel J. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. The lancet. Diabetes & endocrinology, vol.3, no.7, 507-513.

    상세보기

49. Lalloyer, Fanny, Staels, Bart. Fibrates, Glitazones, and Peroxisome Proliferator-Activated Receptors. Arteriosclerosis, thrombosis, and vascular biology, vol.30, no.5, 894-899.

    상세보기

50. Frick, M. Heikki, Elo, Olli, Haapa, Kauko, Heinonen, Olli P., Heinsalmi, Pertti, Helo, Pekka, Huttunen, Jussi K., Kaitaniemi, Pertti, Koskinen, Pekka, Manninen, Vesa, Mäenpää, Hanna, Mälkönen, Marjatta, Mänttäri, Matti, Norola, Seppo, Pasternack, Amos, Pikkarainen, Jarmo, Romo, Matti, Sjöblom, Tom, Nikkilä, Esko A.. Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia. The New England journal of medicine, vol.317, no.20, 1237-1245.

    상세보기

51. Robins, S J, Collins, D, Wittes, J T, Papademetriou, V, Deedwania, P C, Schaefer, E J, McNamara, J R, Kashyap, M L, Hershman, J M, Wexler, L F, Rubins, H B. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.. JAMA : the journal of the American Medical Association, vol.285, no.12, 1585-1591.

    상세보기

52. Circulation Group TBS 21 102 2000 10.1161/01.CIR.102.1.21 Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study. Group TBS. Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000;102:21-27. 

    상세보기

53. Deakin, Sara, Leviev, Ilia, Gomaraschi, Monica, Calabresi, Laura, Franceschini, Guido, James, Richard W.. Enzymatically Active Paraoxonase-1 Is Located at the External Membrane of Producing Cells and Released by a High Affinity, Saturable, Desorption Mechanism. The Journal of biological chemistry, vol.277, no.6, 4301-4308.

    상세보기

54. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. The New England journal of medicine, vol.362, no.17, 1563-1574.

    상세보기

55. Combination Lipid Therapy in Type 2 Diabetes. The New England journal of medicine, vol.363, no.7, 692-695.

    상세보기

56. Nissen, Steven E, Wolski, Kathy, Topol, Eric J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.. JAMA : the journal of the American Medical Association, vol.294, no.20, 2581-2586.

    상세보기

57. Ratner, Robert E, Parikh, Shamik, Tou, Conrad. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, vol.4, no.3, 214-221.

    상세보기

58. Lincoff, A.M.. Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus: The AleCardio Randomized Clinical Trial. JAMA : the journal of the American Medical Association, vol.311, no.15, 1515-.

    상세보기

59. Sahebkar, A., Chew, G.T., Watts, G.F.. Recent advances in pharmacotherapy for hypertriglyceridemia. Progress in lipid research, vol.56, 47-66.

    상세보기

60. Schonfeld, Gustav. Familial hypobetalipoproteinemia: a review. Journal of lipid research, vol.44, no.5, 878-883.

    상세보기

61. Geary, Richard S., Wancewicz, Ed, Matson, John, Pearce, Megan, Siwkowski, Andrew, Swayze, Eric, Bennett, Frank. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochemical pharmacology, vol.78, no.3, 284-291.

    상세보기

62. Bennett, C. Frank, Swayze, Eric E.. RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform. Annual review of pharmacology and toxicology, vol.50, 259-293.

    상세보기

63. McGowan, Mary P., Tardif, Jean-Claude, Ceska, Richard, Burgess, Lesley J., Soran, Handrean, Gouni-Berthold, Ioanna, Wagener, Gilbert, Chasan-Taber, Scott, Lipinski, Michael. Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy. PloS one, vol.7, no.11, e49006-.

    상세보기

64. Santos, Raul D., Duell, P. Barton, East, Cara, Guyton, John R., Moriarty, Patrick M., Chin, Wai, Mittleman, Robert S.. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. European heart journal, vol.36, no.9, 566-575.

    상세보기

65. Curr Opin Lipidol Gregg RE 81 5 1994 10.1097/00041433-199404000-00003 The molecular basis of abetalipoproteinemia. Gregg RE, Wetterau JR. The molecular basis of abetalipoproteinemia. Curr Opin Lipidol. 1994;5:81-86. 

    상세보기

66. Rader, Daniel J., Kastelein, John J.P.. Lomitapide and Mipomersen : Two First-in-Class Drugs for Reducing Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia. Circulation, vol.129, no.9, 1022-1032.

    상세보기

67. for the Phase 3 HoFH Lomitapide Study investigators, Cuchel, M., Meagher, E.A., du Toit Theron, H., Blom, D.J., Marais, A.D., Hegele, R.A., Averna, M.R., Sirtori, C.R., Shah, P.K., Gaudet, D., Stefanutti, C., Vigna, G.B., Du Plessis, A.M., Propert, K.J., Sasiela, W.J., Bloedon, L.T., Rader, D.J.. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. The Lancet, vol.381, no.9860, 40-46.

    상세보기

68. Lee, E-Chiang, Desai, Urvi, Gololobov, Gennady, Hong, Seokjoo, Feng, Xiao, Yu, Xuan-Chuan, Gay, Jason, Wilganowski, Nat, Gao, Cuihua, Du, Ling-Ling, Chen, Joan, Hu, Yi, Zhao, Sharon, Kirkpatrick, Laura, Schneider, Matthias, Zambrowicz, Brian P., Landes, Greg, Powell, David R., Sonnenburg, William K.. Identification of a New Functional Domain in Angiopoietin-like 3 (ANGPTL3) and Angiopoietin-like 4 (ANGPTL4) Involved in Binding and Inhibition of Lipoprotein Lipase (LPL). The Journal of biological chemistry, vol.284, no.20, 13735-13745.

    상세보기

69. FUJIMOTO, Kazunori, KOISHI, Ryuta, SHIMIZUGAWA, Tetsuya, ANDO, Yosuke. Angptl3-null Mice Show Low Plasma Lipid Concentrations by Enhanced Lipoprotein Lipase Activity. Experimental animals, vol.55, no.1, 27-34.

    상세보기

70. Shimizugawa, Tetsuya, Ono, Mitsuru, Shimamura, Mitsuru, Yoshida, Kenichi, Ando, Yosuke, Koishi, Ryuta, Ueda, Kenjiro, Inaba, Toshimori, Minekura, Hiroyuki, Kohama, Takafumi, Furukawa, Hidehiko. ANGPTL3 Decreases Very Low Density Lipoprotein Triglyceride Clearance by Inhibition of Lipoprotein Lipase. The Journal of biological chemistry, vol.277, no.37, 33742-33748.

    상세보기

71. Robciuc, Marius R., Maranghi, Marianna, Lahikainen, Anna, Rader, Daniel, Bensadoun, Andre, Öörni, Katariina, Metso, Jari, Minicocci, Ilenia, Ciociola, Ester, Ceci, Fabrizio, Montali, Anna, Arca, Marcello, Ehnholm, Christian, Jauhiainen, Matti. Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids. Arteriosclerosis, thrombosis, and vascular biology, vol.33, no.7, 1706-1713.

    상세보기

72. Minicocci, Ilenia, Montali, Anna, Robciuc, Marius Robert, Quagliarini, Fabiana, Censi, Vincenzo, Labbadia, Giancarlo, Gabiati, Claudia, Pigna, Giovanni, Sepe, Maria Laura, Pannozzo, Fabio, Lütjohann, Dieter, Fazio, Sergio, Jauhiainen, Matti, Ehnholm, Christian, Arca, Marcello. Mutations in theANGPTL3Gene and Familial Combined Hypolipidemia: A Clinical and Biochemical Characterization. The Journal of clinical endocrinology & metabolism, vol.97, no.7, E1266-E1275.

    상세보기

73. Musunuru, Kiran, Pirruccello, James P., Do, Ron, Peloso, Gina M., Guiducci, Candace, Sougnez, Carrie, Garimella, Kiran V., Fisher, Sheila, Abreu, Justin, Barry, Andrew J., Fennell, Tim, Banks, Eric, Ambrogio, Lauren, Cibulskis, Kristian, Kernytsky, Andrew, Gonzalez, Elena, Rudzicz, Nicholas, Engert, James C., DePristo, Mark A., Daly, Mark J., Cohen, Jonathan C., Hobbs, Helen H., Altshuler, David, Schonfeld, Gustav, Gabriel, Stacey B., Yue, Pin, Kathiresan, Sekar. Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia. The New England journal of medicine, vol.363, no.23, 2220-2227.

    상세보기

74. Pisciotta, Livia, Favari, Elda, Magnolo, Lucia, Simonelli, Sara, Adorni, Maria Pia, Sallo, Raffaella, Fancello, Tatiana, Zavaroni, Ivana, Ardigò, Diego, Bernini, Franco, Calabresi, Laura, Franceschini, Guido, Tarugi, Patrizia, Calandra, Sebastiano, Bertolini, Stefano. Characterization of Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function Mutations of ANGPTL3. Circulation. Cardiovascular genetics, vol.5, no.1, 42-50.

    상세보기

75. Noto, Davide, Cefalù, Angelo B., Valenti, Vincenza, Fayer, Francesca, Pinotti, Elisa, Ditta, Mariangela, Spina, Rossella, Vigna, Giovanni, Yue, Pin, Kathiresan, Sekar, Tarugi, Patrizia, Averna, Maurizio R.. Prevalence of ANGPTL3 and APOB Gene Mutations in Subjects With Combined Hypolipidemia. Arteriosclerosis, thrombosis, and vascular biology, vol.32, no.3, 805-809.

    상세보기

76. Martin-Campos, J.M., Roig, R., Mayoral, C., Martinez, S., Marti, G., Arroyo, J.A., Julve, J., Blanco-Vaca, F.. Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation. Clinica chimica acta, vol.413, no.5, 552-555.

    상세보기

77. Gusarova, Viktoria, Alexa, Corey A., Wang, Yan, Rafique, Ashique, Kim, Jee Hae, Buckler, David, Mintah, Ivory J., Shihanian, Lisa M., Cohen, Jonathan C., Hobbs, Helen H., Xin, Yurong, Valenzuela, David M., Murphy, Andrew J., Yancopoulos, George D., Gromada, Jesper. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. Journal of lipid research, vol.56, no.7, 1308-1317.

    상세보기

78. Atherosclerosis Brandt TA e30 241 2015 10.1016/j.atherosclerosis.2015.04.115 ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers. Brandt TA, Lee RG, Digenio A, Graham MG, Crooke RM, Hughes SG, Singleton W, Witztum JL, Tsimikas S. ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers. Atherosclerosis. 2015;241:e30-e31. 

    상세보기

79. Abifadel, Marianne, Varret, Mathilde, Rabès, Jean-Pierre, Allard, Delphine, Ouguerram, Khadija, Devillers, Martine, Cruaud, Corinne, Benjannet, Suzanne, Wickham, Louise, Erlich, Danièle, Derré, Aurélie, Villéger, Ludovic, Farnier, Michel, Beucler, Isabel, Bruckert, Eric, Chambaz, Jean, Chanu, Bernard, Lecerf, Jean-Michel, Luc, Gerald, Moulin, Philippe, Weissenbach, Jean, Prat, Annick, Krempf, Michel, Junien, Claudine, Seidah, Nabil G, Boileau, Catherine. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature genetics, vol.34, no.2, 154-156.

    상세보기

80. Cohen, Jonathan, Pertsemlidis, Alexander, Kotowski, Ingrid K, Graham, Randall, Garcia, Christine Kim, Hobbs, Helen H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature genetics, vol.37, no.2, 161-165.

    상세보기

81. Cohen, Jonathan C., Boerwinkle, Eric, Mosley Jr., Thomas H., Hobbs, Helen H.. Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart Disease. The New England journal of medicine, vol.354, no.12, 1264-1272.

    상세보기

82. Fasano, Tommaso, Cefalù, Angelo B., Di Leo, Enza, Noto, Davide, Pollaccia, Daniela, Bocchi, Letizia, Valenti, Vincenza, Bonardi, Renato, Guardamagna, Ornella, Averna, Maurizio, Tarugi, Patrizia. A Novel Loss of Function Mutation of PCSK9 Gene in White Subjects With Low-Plasma Low-Density Lipoprotein Cholesterol. Arteriosclerosis, thrombosis, and vascular biology, vol.27, no.3, 677-681.

    상세보기

83. Hooper, A.J., Marais, A.D., Tanyanyiwa, D.M., Burnett, J.R.. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis, vol.193, no.2, 445-448.

    상세보기

84. Zhao, Zhenze, Tuakli-Wosornu, Yetsa, Lagace, Thomas A., Kinch, Lisa, Grishin, Nicholas V., Horton, Jay D., Cohen, Jonathan C., Hobbs, Helen H.. Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote. American journal of human genetics, vol.79, no.3, 514-523.

    상세보기

85. Kwon, Hyock Joo, Lagace, Thomas A., McNutt, Markey C., Horton, Jay D., Deisenhofer, Johann. Molecular basis for LDL receptor recognition by PCSK9. Proceedings of the National Academy of Sciences of the United States of America, vol.105, no.6, 1820-1825.

    상세보기

86. Shapiro, Michael D., Fazio, Sergio, Tavori, Hagai. Targeting PCSK9 for Therapeutic Gains. Current atherosclerosis reports, vol.17, no.4, 19-.

    상세보기

87. Raal, F.J., Giugliano, R.P., Sabatine, M.S., Koren, M.J., Langslet, G., Bays, H., Blom, D., Eriksson, M., Dent, R., Wasserman, S.M., Huang, F., Xue, A., Albizem, M., Scott, R., Stein, E.A.. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology, vol.63, no.13, 1278-1288.

    상세보기

88. Gaudet, D., Kereiakes, D.J., McKenney, J.M., Roth, E.M., Hanotin, C., Gipe, D., Du, Y., Ferrand, A.C., Ginsberg, H.N., Stein, E.A.. Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials). The American journal of cardiology, vol.114, no.5, 711-715.

    상세보기

89. Navarese, Eliano Pio, Kołodziejczak, Michalina, Schulze, Volker, Gurbel, Paul A., Tantry, Udaya, Lin, Yingfeng, Brockmeyer, Maximilian, Kandzari, David E., Kubica, Julia M., D'Agostino Sr., Ralph B., Kubica, Jacek, Volpe, Massimo, Agewall, Stefan, Kereiakes, Dean J., Kelm, Malte. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia : A Systematic Review and Meta-analysis. Annals of internal medicine, vol.163, no.1, 40-51.

    상세보기

90. Goldstein, J L, Brown, M S. The LDL Receptor Locus and the Genetics of Familial Hypercholesterolemia. Annual review of genetics, vol.13, 259-289.

    상세보기

91. A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-PCSsc), Targeting PCSK9 for the Treatment of Hypercholesterolemia: Initial Phase 1 Study Results Abstract presented at European Society of Cardiology Fitzgerald K Fitzgerald K, Simon A, White S, Borodovsky A, Patel N, Bettencourt B, Clausen V, Wijngaard P, Horton J, Kauffman R, Kallend D. A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-PCSsc), Targeting PCSK9 for the Treatment of Hypercholesterolemia: Initial Phase 1 Study Results Abstract presented at European Society of Cardiology. August 30, 2015; London. 

92. Pinkosky, Stephen L., Filippov, Sergey, Srivastava, Rai Ajit K., Hanselman, Jeffrey C., Bradshaw, Cheryl D., Hurley, Timothy R., Cramer, Clay T., Spahr, Mark A., Brant, Ashley F., Houghton, Jacob L., Baker, Chris, Naples, Mark, Adeli, Khosrow, Newton, Roger S.. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. Journal of lipid research, vol.54, no.1, 134-151.

    상세보기

93. Bergeron, Raynald, Ren, Jian Ming, Cadman, Kevin S., Moore, Irene K., Perret, Pascale, Pypaert, Marc, Young, Lawrence H., Semenkovich, Clay F., Shulman, Gerald I.. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. American journal of physiology, Endocrinology and metabolism, vol.281, no.6, E1340-E1346.

    상세보기

94. Gutierrez, Maria J., Rosenberg, Noah L., MacDougall, Diane E., Hanselman, Jeffrey C., Margulies, Janice R., Strange, Poul, Milad, Mark A., McBride, Scott J., Newton, Roger S.. Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus. Arteriosclerosis, thrombosis, and vascular biology, vol.34, no.3, 676-683.

    상세보기

95. Thompson, P.D., Rubino, J., Janik, M.J., MacDougall, D.E., McBride, S.J., Margulies, J.R., Newton, R.S.. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. Journal of clinical lipidology, vol.9, no.3, 295-304.

    상세보기

96. Fisher, Edward A., Feig, Jonathan E., Hewing, Bernd, Hazen, Stanley L., Smith, Jonathan D.. High-Density Lipoprotein Function, Dysfunction, and Reverse Cholesterol Transport. Arteriosclerosis, thrombosis, and vascular biology, vol.32, no.12, 2813-2820.

    상세보기

97. Feingold, Kenneth R., Grunfeld, Carl. The role of HDL in innate immunity. Journal of lipid research, vol.52, no.1, 1-3.

    상세보기

98. Drew, Brian G., Duffy, Stephen J., Formosa, Melissa F., Natoli, Alaina K., Henstridge, Darren C., Penfold, Sally A., Thomas, Walter G., Mukhamedova, Nigora, de Courten, Barbora, Forbes, Josephine M., Yap, Felicia Y., Kaye, David M., van Hall, Gerrit, Febbraio, Mark A., Kemp, Bruce E., Sviridov, Dmitri, Steinberg, Gregory R., Kingwell, Bronwyn A.. High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus. Circulation, vol.119, no.15, 2103-2111.

    상세보기

99. Thomson, Russell, Genovese, Giulio, Canon, Chelsea, Kovacsics, Daniella, Higgins, Matthew K., Carrington, Mark, Winkler, Cheryl A., Kopp, Jeffrey, Rotimi, Charles, Adeyemo, Adebowale, Doumatey, Ayo, Ayodo, George, Alper, Seth L., Pollak, Martin R., Friedman, David J., Raper, Jayne. Evolution of the primate trypanolytic factor APOL1. Proceedings of the National Academy of Sciences of the United States of America, vol.111, no.20, E2130-E2139.

    상세보기

100. De Nardo, Dominic, Labzin, Larisa I., Kono, Hajime, Seki, Reiko, Schmidt, Susanne V., Beyer, Marc, Xu, Dakang, Zimmer, Sebastian, Lahrmann, Catharina, Schildberg, Frank A., Vogelhuber, Johanna, Kraut, Michael, Ulas, Thomas, Kerksiek, Anja, Krebs, Wolfgang, Bode, Niklas, Grebe, Alena, Fitzgerald, Michael L., Hernandez, Nicholas J., Williams, Bryan, Knolle, Percy, Kneilling, Manfred, Röcken, Martin, Lütjohann, Dieter, Wright, Samuel D., Schultze, Joachim L., Latz, Eicke. High density lipoprotein mediates anti-inflammatory transcriptional reprogramming of macrophages via the transcriptional repressor ATF3. Nature immunology, vol.15, no.2, 152-160.

     상세보기

101. Rosenson, Robert S, Brewer Jr, H Bryan, Chapman, M John, Fazio, Sergio, Hussain, M Mahmood, Kontush, Anatol, Krauss, Ronald M, Otvos, James D, Remaley, Alan T, Schaefer, Ernst J. HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events. Clinical chemistry, vol.57, no.3, 392-410.

     상세보기

102. Heinecke, Jay W.. The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. Journal of lipid research, vol.50, no.suppl, S167-S171.

     상세보기

103. Kontush, Anatol, Lhomme, Marie, Chapman, M. John. Unraveling the complexities of the HDL lipidome. Journal of lipid research, vol.54, no.11, 2950-2963.

     상세보기

104. Evans, G F, Bensch, W R, Apelgren, L D, Bailey, D, Kauffman, R F, Bumol, T F, Zuckerman, S H. Inhibition of cholesteryl ester transfer protein in normocholesterolemic and hypercholesterolemic hamsters: effects on HDL subspecies, quantity, and apolipoprotein distribution.. Journal of lipid research, vol.35, no.9, 1634-1645.

     상세보기

105. Ballantyne, Christie M., Miller, Michael, Niesor, Eric J., Burgess, Tracy, Kallend, David, Stein, Evan A.. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study. The American heart journal, vol.163, no.3, 515-521.e3.

     상세보기

106. Yvan-Charvet, Laurent, Kling, Jelena, Pagler, Tamara, Li, Hongna, Hubbard, Brian, Fisher, Tim, Sparrow, Carl P., Taggart, Andrew K., Tall, Alan R.. Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib. Arteriosclerosis, thrombosis, and vascular biology, vol.30, no.7, 1430-1438.

     상세보기

107. Cannon, Christopher P., Shah, Sukrut, Dansky, Hayes M., Davidson, Michael, Brinton, Eliot A., Gotto Jr., Antonio M., Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B., Zafarino, Jennifer, Mitchel, Yale, Barter, Philip. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. The New England journal of medicine, vol.363, no.25, 2406-2415.

     상세보기

108. DEFINE Investigators, Gotto, A.M., Cannon, C.P., Li, X.S., Vaidya, S., Kher, U., Brinton, E.A., Davidson, M., Moon, J.E., Shah, S., Dansky, H.M., Mitchel, Y., Barter, P.. Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease. The American journal of cardiology, vol.113, no.1, 76-83.

     상세보기

109. Kastelein, J.J.P., Besseling, J., Shah, S., Bergeron, J., Langslet, G., Hovingh, G.K., Al-Saady, N., Koeijvoets, M., Hunter, J., Johnson-Levonas, A.O., Fable, J., Sapre, A., Mitchel, Y.. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet, vol.385, no.9983, 2153-2161.

     상세보기

110. Hovingh, G.K., Kastelein, J.J.P., van Deventer, S.J.H., Round, P., Ford, J., Saleheen, D., Rader, D.J., Brewer, H.B., Barter, P.J.. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet, vol.386, no.9992, 452-460.

     상세보기

111. Fielding, C J, Fielding, P E. Molecular physiology of reverse cholesterol transport.. Journal of lipid research, vol.36, no.2, 211-228.

     상세보기

112. Oram, John F., Lawn, Richard M.. ABCA1: the gatekeeper for eliminating excess tissue cholesterol. Journal of lipid research, vol.42, no.8, 1173-1179.

     상세보기

113. Sirtori, Cesare R., Calabresi, Laura, Franceschini, Guido, Baldassarre, Damiano, Amato, Mauro, Johansson, Jan, Salvetti, Massimo, Monteduro, Cristina, Zulli, Roberto, Muiesan, Maria L., Agabiti-Rosei, Enrico. Cardiovascular Status of Carriers of the Apolipoprotein A-I _Milano Mutant : The Limone sul Garda Study. Circulation, vol.103, no.15, 1949-1954.

     상세보기

114. Nissen, Steven E., Tsunoda, Taro, Tuzcu, E. Murat, Schoenhagen, Paul, Cooper, Christopher J., Yasin, Muhammad, Eaton, Gregory M., Lauer, Michael A., Sheldon, W. Scott, Grines, Cindy L., Halpern, Stephen, Crowe, Tim, Blankenship, James C., Kerensky, Richard. Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes : A Randomized Controlled Trial. JAMA : the journal of the American Medical Association, vol.290, no.17, 2292-.

     상세보기

115. Tardif, J.-C., Gregoire, J., L Allier, P. L., Ibrahim, R., Lesperance, J., Heinonen, T. M., Kouz, S., Berry, C., Basser, R., Lavoie, M.-A.. Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis: A Randomized Controlled Trial. JAMA : the journal of the American Medical Association, vol.297, no.15, 1675-1682.

     상세보기

116. Martínez-Beamonte, Roberto, Lou-Bonafonte, Jose M., Martínez-Gracia, María V., Osada, Jesús. Sphingomyelin in High-Density Lipoproteins: Structural Role and Biological Function. International journal of molecular sciences, vol.14, no.4, 7716-7741.

     상세보기

117. Tardif, Jean-Claude, Ballantyne, Christie M., Barter, Philip, Dasseux, Jean-Louis, Fayad, Zahi A., Guertin, Marie-Claude, Kastelein, John J. P., Keyserling, Constance, Klepp, Heather, Koenig, Wolfgang, L'Allier, Philippe L., Lespérance, Jacques, Lüscher, Thomas F., Paolini, John F., Tawakol, Ahmed, Waters, David D., Pfeffer, M., Brown, V., Rouleau, J., Watkins, P., Wei, L.J., Gosselin, G., Chayer, C., Lanthier, S., Pelletier, G.B., Racine, N., Agarwal, H., Brilakis, E., Cannon, L., Carrié, D., Corbelli, J., Coste, P., de Winter, R., Diaz, A., Eisenberg, S., Ennis, B., Fajadet, J., Fam, N., Fortuin, D., Gessler, C., Grines, C., Guerra, D., Gum, H., Haldis, T., Heestermans, T., Herrman, J.P., Huynh, T., Kedhi, E., Koren, M., Kouz, S., Krolick, M., Kumkumian, G., Lavi, S., Li, R.J., Masud, ARZ, McAlhany, C., McGrew, F.A., O'Shaughnessy, C., Oude Ophuis, A.J.M., Parr, K., Penny, W., Pesant, Y., Post, H., Robi. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial ^†. European heart journal, vol.35, no.46, 3277-3286.

     상세보기

118. Atherosclerosis Hovingh GK e13 10.1016/j.atherosclerosis.2014.05.008 235 Effects of CER-001 on carotid atherosclerosis by 3tmri in homozygous familial hypercholesterolemia (HoFH): the modifying orphan disease evaluation (MODE) study. Hovingh GK, Stroes ES, Gaudet D, Stefanutti C, Soran H, Kwok S, de Graaf J, Kastelijn JJP, Frick J, Klepp H, Keyserling C, Paolini J, Dasseux JL. Effects of CER-001 on carotid atherosclerosis by 3tmri in homozygous familial hypercholesterolemia (HoFH): the modifying orphan disease evaluation (MODE) study. Atherosclerosis. 235:e13-e14. 

     상세보기

119. Hovingh, G. Kees, Smits, Loek P., Stefanutti, Claudia, Soran, Handrean, Kwok, See, de Graaf, Jacqueline, Gaudet, Daniel, Keyserling, Constance H., Klepp, Heather, Frick, Jennifer, Paolini, John F., Dasseux, Jean-Louis, Kastelein, John J.P., Stroes, Erik S.. The effect of an apolipoprotein A-I–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia : The Modifying Orphan Disease Evaluation (MODE) study. The American heart journal, vol.169, no.5, 736-742.e1.

     상세보기

120. Sacks, Frank M., Rudel, Lawrence L., Conner, Adam, Akeefe, Hassibullah, Kostner, Gerhard, Baki, Talal, Rothblat, George, de la Llera-Moya, Margarita, Asztalos, Bela, Perlman, Timothy, Zheng, Chunyu, Alaupovic, Petar, Maltais, Jo-Ann B., Brewer, H. Bryan. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. Journal of lipid research, vol.50, no.5, 894-907.

     상세보기

121. Waksman, R., Torguson, R., Kent, K.M., Pichard, A.D., Suddath, W.O., Satler, L.F., Martin, B.D., Perlman, T.J., Maltais, J.A.B., Weissman, N.J., Fitzgerald, P.J., Brewer, H.B.. A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology, vol.55, no.24, 2727-2735.

     상세보기

122. Khetarpal, Sumeet A., Rader, Daniel J.. Triglyceride-Rich Lipoproteins and Coronary Artery Disease Risk : New Insights From Human Genetics. Arteriosclerosis, thrombosis, and vascular biology, vol.35, no.2, e3-e9.

     상세보기

123. Do, Ron, Willer, Cristen J, Schmidt, Ellen M, Sengupta, Sebanti, Gao, Chi, Peloso, Gina M, Gustafsson, Stefan, Kanoni, Stavroula, Ganna, Andrea, Chen, Jin, Buchkovich, Martin L, Mora, Samia, Beckmann, Jacques S, Bragg-Gresham, Jennifer L, Chang, Hsing-Yi, Demirkan, Ay?e, Den Hertog, Heleen M, Donnelly, Louise A, Ehret, Georg B, Esko, Tonu, Feitosa, Mary F, Ferreira, Teresa, Fischer, Krista, Fontanillas, Pierre, Fraser, Ross M, Freitag, Daniel F, Gurdasani, Deepti, Heikkila, Kauko, Hypponen, Elina, Isaacs, Aaron, Jackson, Anne U, Johansson, Asa, Johnson, Toby, Kaakinen, Marika, Kettunen, Johannes, Kleber, Marcus E, Li, Xiaohui, Luan, Jian'an, Lyytikainen, Leo-Pekka, Magnusson, Patrik K E, Mangino, Massimo, Mihailov, Evelin, Montasser, May E, Muller-Nurasyid, Martina, Nolte, Ilja M, O'Connell, Jeffrey R, Palmer, Cameron D, Perola, Markus, Petersen, Ann-Kristin, Sanna, Serena. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nature genetics, vol.45, no.11, 1345-1352.

     상세보기

124. Saraswathi, Viswanathan, Hasty, Alyssa H.. The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages. Journal of lipid research, vol.47, no.7, 1406-1415.

     상세보기

125. Varbo, Anette, Benn, Marianne, Tybjærg-Hansen, Anne, Nordestgaard, Børge G.. Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation. Circulation, vol.128, no.12, 1298-1309.

     상세보기

126. Tatsuno, Ichiro. Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia. Expert review of cardiovascular therapy, vol.12, no.11, 1261-1268.

     상세보기

127. Mozaffarian, Dariush, Wu, Jason H.Y.. (n-3) Fatty Acids and Cardiovascular Health: Are Effects of EPA and DHA Shared or Complementary?. The Journal of nutrition, vol.142, no.3, 614S-625S.

     상세보기

128. The Lancet Investigators GI-P. 447 354 1999 10.1016/S0140-6736(99)07072-5 Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Investigators GI-P. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. The Lancet. 1999;354:447-455. 

     상세보기

129. Lancet GISSI-HF Investigators 1223 10.1016/S0140-6736(08)61239-8 372 Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 372:1223-1230. 

     상세보기

130. Yokoyama, Mitsuhiro, Origasa, Hideki, Matsuzaki, Masunori, Matsuzawa, Yuji, Saito, Yasushi, Ishikawa, Yuichi, Oikawa, Shinichi, Sasaki, Jun, Hishida, Hitoshi, Itakura, Hiroshige, Kita, Toru, Kitabatake, Akira, Nakaya, Noriaki, Sakata, Toshiie, Shimada, Kazuyuki, Shirato, Kunio. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. The Lancet, vol.369, no.9567, 1090-1098.

     상세보기

131. 10.1001/jamainternmed.2013.12765 

     

132. Roth, Eli M. ω-3 carboxylic acids for hypertriglyceridemia. Expert opinion on pharmacotherapy, vol.16, no.1, 123-133.

     상세보기

133. Ballantyne, Christie M., Bays, Harold E., Kastelein, John J., Stein, Evan, Isaacsohn, Jonathan L., Braeckman, Rene A., Soni, Paresh N.. Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study). The American journal of cardiology, vol.110, no.7, 984-992.

     상세보기

134. Bays, H.E., Ballantyne, C.M., Kastelein, J.J., Isaacsohn, J.L., Braeckman, R.A., Soni, P.N.. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial). The American journal of cardiology, vol.108, no.5, 682-690.

     상세보기

135. Blair, Hannah A., Dhillon, Sohita. Omega-3 Carboxylic Acids (Epanova®): A Review of Its Use in Patients with Severe Hypertriglyceridemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, vol.14, no.5, 393-400.

     상세보기

136. 10.1161/circ.130.suppl_2.18507 

     

137. Presented at International Symposium on Atherosclerosis 2015 Bays H Bays H, Hallen J, Vige R. Icosabutate for the treatment of very high triglycerides: a placebo-controlled, randomized, double-blind, 12-week proof-of-concept study. Presented at International Symposium on Atherosclerosis 2015; May 26. 2015. 

138. Loss-of-Function Mutations inAPOC3,Triglycerides, and Coronary Disease. The New England journal of medicine, vol.371, no.1, 22-31.

     상세보기

139. Jørgensen, Anders Berg, Frikke-Schmidt, Ruth, Nordestgaard, Børge G., Tybjærg-Hansen, Anne. Loss-of-Function Mutations inAPOC3and Risk of Ischemic Vascular Disease. The New England journal of medicine, vol.371, no.1, 32-41.

     상세보기

140. Pollin, Toni I., Damcott, Coleen M., Shen, Haiqing, Ott, Sandra H., Shelton, John, Horenstein, Richard B., Post, Wendy, McLenithan, John C., Bielak, Lawrence F., Peyser, Patricia A., Mitchell, Braxton D., Miller, Michael, O'Connell, Jeffrey R., Shuldiner, Alan R.. A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection. Science, vol.322, no.5908, 1702-1705.

     상세보기

141. Qin, Wen, Sundaram, Meenakshi, Wang, Yuwei, Zhou, Hu, Zhong, Shumei, Chang, Chia-Ching, Manhas, Sanjay, Yao, Erik F., Parks, Robin J., McFie, Pamela J., Stone, Scot J., Jiang, Zhenghui G., Wang, Congrong, Figeys, Daniel, Jia, Weiping, Yao, Zemin. Missense Mutation in APOC3 within the C-terminal Lipid Binding Domain of Human ApoC-III Results in Impaired Assembly and Secretion of Triacylglycerol-rich Very Low Density Lipoproteins. The Journal of biological chemistry, vol.286, no.31, 27769-27780.

     상세보기

142. Gaudet, Daniel, Brisson, Diane, Tremblay, Karine, Alexander, Veronica J., Singleton, Walter, Hughes, Steven G., Geary, Richard S., Baker, Brenda F., Graham, Mark J., Crooke, Rosanne M., Witztum, Joseph L.. Targeting APOC3 in the Familial Chylomicronemia Syndrome. The New England journal of medicine, vol.371, no.23, 2200-2206.

     상세보기

143. Gaudet, Daniel, Alexander, Veronica J., Baker, Brenda F., Brisson, Diane, Tremblay, Karine, Singleton, Walter, Geary, Richard S., Hughes, Steven G., Viney, Nicholas J., Graham, Mark J., Crooke, Rosanne M., Witztum, Joseph L., Brunzell, John D., Kastelein, John J.P.. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. The New England journal of medicine, vol.373, no.5, 438-447.

     상세보기

144. Stroes, Erik S., Nierman, Melchior C., Meulenberg, Janneke J., Franssen, Remco, Twisk, Jaap, Henny, C. Pieter, Maas, Mario M., Zwinderman, Aeilko H., Ross, Colin, Aronica, Eleonora, High, Katherine A., Levi, Marcel M., Hayden, Michael R., Kastelein, John J., Kuivenhoven, Jan Albert. Intramuscular Administration of AAV1-Lipoprotein Lipase ^S447X Lowers Triglycerides in Lipoprotein Lipase-Deficient Patients. Arteriosclerosis, thrombosis, and vascular biology, vol.28, no.12, 2303-2304.

     상세보기

145. J Clin Lipidol Meyers C 266 10.1016/j.jacl.2012.04.034 6 The DGAT1 inhibitor LCQ908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome. Meyers C, Gaudet D, Tremblay K, Amer A, Chen J, Aimin F. The DGAT1 inhibitor LCQ908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome. J Clin Lipidol. 6:266-267. 

     상세보기

146. Albers, J J, Kennedy, H, Marcovina, S M. Evidence that Lp[a] contains one molecule of apo[a] and one molecule of apoB: evaluation of amino acid analysis data.. Journal of lipid research, vol.37, no.1, 192-196.

     상세보기

147. Kamstrup, Pia R.. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA : the journal of the American Medical Association, vol.301, no.22, 2331-.

     상세보기

148. Clarke, Robert, Peden, John F., Hopewell, Jemma C., Kyriakou, Theodosios, Goel, Anuj, Heath, Simon C., Parish, Sarah, Barlera, Simona, Franzosi, Maria Grazia, Rust, Stephan, Bennett, Derrick, Silveira, Angela, Malarstig, Anders, Green, Fiona R., Lathrop, Mark, Gigante, Bruna, Leander, Karin, de Faire, Ulf, Seedorf, Udo, Hamsten, Anders, Collins, Rory, Watkins, Hugh, Farrall, Martin. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. The New England journal of medicine, vol.361, no.26, 2518-2528.

     상세보기

149. Li, Yonghong, Luke, May M., Shiffman, Dov, Devlin, James J.. Genetic Variants in the Apolipoprotein(a) Gene and Coronary Heart Disease. Circulation. Cardiovascular genetics, vol.4, no.5, 565-573.

     상세보기

150. Lamon-Fava, Stefania, Marcovina, Santica M., Albers, John J., Kennedy, Hal, DeLuca, Carl, White, Charles C., Cupples, L. Adrienne, McNamara, Judith R., Seman, Leo J., Bongard, Vanina, Schaefer, Ernst J.. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. Journal of lipid research, vol.52, no.6, 1181-1187.

     상세보기

151. Danesh, John, Collins, Rory, Peto, Richard. Lipoprotein(a) and Coronary Heart Disease : Meta-Analysis of Prospective Studies. Circulation, vol.102, no.10, 1082-1085.

     상세보기

152. Eaton, D L, Fless, G M, Kohr, W J, McLean, J W, Xu, Q T, Miller, C G, Lawn, R M, Scanu, A M. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen.. Proceedings of the National Academy of Sciences of the United States of America, vol.84, no.10, 3224-3228.

     상세보기

153. Khera, Amit V., Everett, Brendan M., Caulfield, Michael P., Hantash, Feras M., Wohlgemuth, Jay, Ridker, Paul M, Mora, Samia. Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk : An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation, vol.129, no.6, 635-642.

     상세보기

154. Albers, J.J., Slee, A., O'Brien, K.D., Robinson, J.G., Kashyap, M.L., Kwiterovich, P.O., Xu, P., Marcovina, S.M.. Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes. Journal of the American College of Cardiology, vol.62, no.17, 1575-1579.

     상세보기

155. Leebmann, Josef, Roeseler, Eberhard, Julius, Ulrich, Heigl, Franz, Spitthoever, Ralf, Heutling, Dennis, Breitenberger, Paul, Maerz, Winfried, Lehmacher, Walter, Heibges, Andreas, Klingel, Reinhard. Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease : Prospective Observational Multicenter Study. Circulation, vol.128, no.24, 2567-2576.

     상세보기

156. Davidson, M.H., Ballantyne, C.M., Jacobson, T.A., Bittner, V.A., Braun, L.T., Brown, A.S., Brown, W., Cromwell, W.C., Goldberg, R.B., McKenney, J.M., Remaley, A.T., Sniderman, A.D., Toth, P.P., Tsimikas, S., Ziajka, P.E., Maki, K.C., Dicklin, M.R.. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of clinical lipidology, vol.5, no.5, 338-367.

     상세보기

157. Nordestgaard, Børge G., Chapman, M. John, Ray, Kausik, Borén, Jan, Andreotti, Felicita, Watts, Gerald F., Ginsberg, Henry, Amarenco, Pierre, Catapano, Alberico, Descamps, Olivier S., Fisher, Edward, Kovanen, Petri T., Kuivenhoven, Jan Albert, Lesnik, Philippe, Masana, Luis, Reiner, Zeljko, Taskinen, Marja-Riitta, Tokgözoglu, Lale, Tybjærg-Hansen, Anne. Lipoprotein(a) as a cardiovascular risk factor: current status. European heart journal, vol.31, no.23, 2844-2853.

     상세보기

158. Tsimikas, S., Viney, N.J., Hughes, S.G., Singleton, W., Graham, M.J., Baker, B.F., Burkey, J.L., Yang, Q., Marcovina, S.M., Geary, R.S., Crooke, R.M., Witztum, J.L.. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. The Lancet, vol.386, no.10002, 1472-1483.

     상세보기

159. Prakash, Thazha P., Graham, Mark J., Yu, Jinghua, Carty, Rick, Low, Audrey, Chappell, Alfred, Schmidt, Karsten, Zhao, Chenguang, Aghajan, Mariam, Murray, Heather F., Riney, Stan, Booten, Sheri L., Murray, Susan F., Gaus, Hans, Crosby, Jeff, Lima, Walt F., Guo, Shuling, Monia, Brett P., Swayze, Eric E., Seth, Punit P.. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N -acetyl galactosamine improves potency 10-fold in mice. Nucleic acids research, vol.42, no.13, 8796-8807.

     상세보기

160. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet, vol.375, no.9709, 132-140.

     상세보기

161. C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. The New England journal of medicine, vol.367, no.14, 1310-1320.

     상세보기

162. Ridker, Paul M., Rifai, Nader, Pfeffer, Marc A., Sacks, Frank, Braunwald, Eugene. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein. Circulation, vol.100, no.3, 230-235.

     상세보기

163. Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene. C-Reactive Protein Levels and Outcomes after Statin Therapy. The New England journal of medicine, vol.352, no.1, 20-28.

     상세보기

164. Ridker, Paul M., Rifai, Nader, Clearfield, Michael, Downs, John R., Weis, Stephen E., Miles, J. Shawn, Gotto Jr., Antonio M.. Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events. The New England journal of medicine, vol.344, no.26, 1959-1965.

     상세보기

165. Ridker, Paul M, Danielson, Eleanor, Fonseca, Francisco A.H., Genest, Jacques, Gotto Jr., Antonio M., Kastelein, John J.P., Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J., MacFadyen, Jean G., Nordestgaard, Børge G., Shepherd, James, Willerson, James T., Glynn, Robert J.. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. The New England journal of medicine, vol.359, no.21, 2195-2207.

     상세보기

166. Tardif, J.C., Tanguay, J.F., Wright, S.R., Duchatelle, V., Petroni, T., Gregoire, J.C., Ibrahim, R., Heinonen, T.M., Robb, S., Bertrand, O.F., Cournoyer, D., Johnson, D., Mann, J., Guertin, M.C., L'Allier, P.L.. Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non-ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, vol.61, no.20, 2048-2055.

     상세보기

167. Micha, Renata, Imamura, Fumiaki, Wyler von Ballmoos, Moritz, Solomon, Daniel H., Hernán, Miguel A., Ridker, Paul M., Mozaffarian, Dariush. Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease. The American journal of cardiology, vol.108, no.9, 1362-1370.

     상세보기

168. Strowig, Till, Henao-Mejia, Jorge, Elinav, Eran, Flavell, Richard. Inflammasomes in health and disease. Nature, vol.481, no.7381, 278-286.

     상세보기

169. Duewell, Peter, Kono, Hajime, Rayner, Katey J., Sirois, Cherilyn M., Vladimer, Gregory, Bauernfeind, Franz G., Abela, George S., Franchi, Luigi, Nuñez, Gabriel, Schnurr, Max, Espevik, Terje, Lien, Egil, Fitzgerald, Katherine A, Rock, Kenneth L., Moore, Kathryn J., Wright, Samuel D, Hornung, Veit, Latz, Eicke. NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature, vol.464, no.7293, 1357-1361.

     상세보기

170. Rajamäki, Kristiina, Lappalainen, Jani, Öörni, Katariina, Välimäki, Elina, Matikainen, Sampsa, Kovanen, Petri T., Eklund, Kari K.. Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation. PloS one, vol.5, no.7, e11765-.

     상세보기

171. Abela, G.S.. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. Journal of clinical lipidology, vol.4, no.3, 156-164.

     상세보기

172. Ridker, Paul M, Thuren, Tom, Zalewski, Andrew, Libby, Peter. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). The American heart journal, vol.162, no.4, 597-605.

     상세보기

173. Ridker, Paul M, Howard, Campbell P., Walter, Verena, Everett, Brendan, Libby, Peter, Hensen, Johannes, Thuren, Tom. Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen : A Phase IIb Randomized, Placebo-Controlled Trial. Circulation, vol.126, no.23, 2739-2748.

     상세보기

174. Khera, Amit V, Natarajan, Pradeep, Kathiresan, Sekar. The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?. European journal of preventive cardiology, vol.23, no.10, 1062-1064.

     상세보기